Alexandra Mancini

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada.

Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.